(888) 352-RUSH for help arranging an appointment.
Faculty Rank: Assistant Professor
Medical or Graduate Education:
Oregon Health & Science University School of Medicine
University of Illinois Medical Center - Internal Medicine
Rush University Medical Center - Hematology/Oncology
Bile duct cancer
Squamous cell carcinoma
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM. J Immunother. 2012 2012 Oct 35(8):629-40. A Patient With Metastatic Adenocarcinoma of the Jejunum Who Had a Prolonged Complete Response to FOLFOX. Lai S, Leslie W. Gastrointest Cancer Res. 2012 2012 Mar 5(2):71-2. No abstract available. Successful treatment of anal carcinoma with Paclitaxel, Cisplatin, and radiotherapy in a patient who developed a coronary syndrome from 5-fu. Garg S, Abrams RA, Leslie WT. Gastrointest Cancer Res. 2012 2012 Jul 5(4):135-6. No abstract available. Treatment of recurrent pediatric gastrointestinal stromal tumors. Dave M, Jimenez A, Evans K, Leslie W. Gastrointest Cancer Res. 2012 2012 Jul 5(4):139-40. No abstract available. Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma. Lai S, Venugopal P, Leslie W. Clin Adv Hematol Oncol. 2012 2012 Feb 10(2):134-6. No abstract available. Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Therapy and Concurrent Full-Dose Gemcitabine: Analysis of a Prospective Phase 1/2 Dose Escalation Study. Vainshtein JM, Schipper M, Zalupski MM, Lawrence TS, Abrams R, Francis IR, Khan G, Leslie W, Ben-Josef E. Int J Radiat Oncol Biol Phys. 2012 2012 Dec 19. doi:pii: S0360-3016(12)03817-5. 10.1016/j.ijrobp.2012.11.020. [Epub ahead of print] A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, Normolle D, Simeone DM, Sonnenday C, Abrams R, Leslie W, Khan G, Zalupski MM. Int J Radiat Oncol Biol Phys. 2012 2012 Dec 1 84(5):1166-71. doi: 10.1016/j.ijrobp.2012.02.051. Epub 2012 Apr 27. A patient with necrobiotic xanthogranuloma presenting with an anterior mediastinal mass, plasma cell dyscrasia, and a lymphoproliferative disorder. Chen KY, Leslie W, Mahon B, Venugopal P. Clin Adv Hematol Oncol. 2011 2011 Sep 9(9):696-700. No abstract available. Prolonged neutropenia after neoadjuvant radiation therapy and chemotherapy using oxaliplatin and capecitabine for rectal cancer. McFarland DC, Leslie WT. Gastrointest Cancer Res. 2011 Jan 4(1):33-5 An Epstein-Barr virus-associated smooth muscle tumor successfully treated with surgical resection: a case report and literature review Cela I, Shah NB, Bradly D, Loew J, Leslie W Clin Adv Hematol Oncol 2010 Jun 8(6):423-6 Neoadjuvant treatment of rectal gastrointestinal stromal tumors with imatinib. Turner J, Batus M, Leslie W, Coogan C, Saclarides TJ. Am Surg. 2010 Aug 76(8):E110-2 Management of a patient with borderline resectable pancreatic cancer. Case report and review Shah AP, Strauss JB, Leslie WT, Shah A, Mahon B, Abrams RA Oncology (Williston Park) 2008 Nov 30 22(13):1524-9 Localized bone disease as a presentation of hairy cell leukemia Karmali R, Farhat M, Leslie W, McIntire MG, Gregory S Clin Adv Hematol Oncol 2008 Apr 6(4):290-4
To watch a brief video of William T. Leslie, MD, click the play button at the lower left corner of the video frame below.
(If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
I treat the gastrointestinal cancers, which includes colon cancer, stomach cancer, pancreas cancer. We do the medical oncology part and there’s also radiation oncology, surgery. So it’s kind of a combined effort.
There are a lot of different drugs that are available, so patients have better outcomes and we’ve got a lot of long-term survivors. You know, people say, “Isn’t it depressing to treat these cancer patients?” But a lot of people are cured, especially for colon cancer or anal cancer, rectal cancer. Within 10 to 15 years we’re going to take the patient’s tumor, analyze all the genes in the tumor and make like a designer treatment for that patient. We’re not there yet, but at Rush we’re testing for some of those genes already.